• The dose-escalation results of JSKN003 was reported at this AACR conference.
• JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100%. No DLT was observed, MTD has not been reached yet.

SU...